NCT02672566View on ClinicalTrials.gov

Low-molecular-weight Heparin in Constituted Vascular Intrauterine Growth Restriction

PHASE3CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

July 22, 2016

Primary Completion Date

September 5, 2019

Study Completion Date

January 22, 2020

Conditions
Fetal Growth Retardation
Interventions
DRUG

Enoxaparin

Enoxaparin will be delivered to the patients every day at the dose of 4 000 Ui.

OTHER

Usual care

Patients will all benefit from the usual care

Trial Locations (8)

38000

Chu Grenoble, Grenoble

42100

Chu Saint Etienne, Saint-Etienne

63003

Chu Clermont-Ferrand, Clermont-Ferrand

Unknown

Chru Brest, Brest

Ch Lyon Sud Pierre Benite, Lyon

HFME - Lyon Est, Lyon

Hopital Croix Rousse Lyon, Lyon

Ch Roanne, Roanne

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Saint Etienne

OTHER

NCT02672566 - Low-molecular-weight Heparin in Constituted Vascular Intrauterine Growth Restriction | Biotech Hunter | Biotech Hunter